You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

258 Results
Imprimer Ces renseignements doivent aider les fournisseurs de soins de santé à se préparer à mener des conversations avec leurs patientes et...
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Palliative
Funding:
ODB - General Benefit
    abiraterone
Exceptional Access Program
    olaparib - In combination with abiraterone, and prednisone or prednisolone for the treatment of metastatic castration resistant prostate cancer (mCRPC), based on criteria
ODB - General Benefit
    prednisone
Dec 2024
Guidelines and Advice
Drug
Other Name(s): Tecentriq® SC
Jul 2025
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Hodgkin
Intent: Curative
May 2025

Pages